Short Interest in Gossamer Bio Inc (NASDAQ:GOSS) Rises By 21.0%

Gossamer Bio Inc (NASDAQ:GOSS) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 4,380,000 shares, a growth of 21.0% from the December 15th total of 3,620,000 shares. Currently, 10.2% of the company’s stock are sold short. Based on an average daily volume of 593,000 shares, the short-interest ratio is currently 7.4 days.

In other news, insider Jakob Dupont sold 1,994 shares of Gossamer Bio stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $15.81, for a total transaction of $31,525.14. Following the transaction, the insider now owns 1,994 shares in the company, valued at approximately $31,525.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 23.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can increased its holdings in shares of Gossamer Bio by 144.7% during the 2nd quarter. Bank of Montreal Can now owns 2,839 shares of the company’s stock worth $63,000 after acquiring an additional 1,679 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Gossamer Bio by 39.3% during the 2nd quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock worth $154,000 after acquiring an additional 1,967 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Gossamer Bio by 87.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,995 shares of the company’s stock worth $126,000 after acquiring an additional 2,798 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Gossamer Bio by 4.8% during the 3rd quarter. Redmile Group LLC now owns 260,500 shares of the company’s stock worth $4,374,000 after acquiring an additional 11,900 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Gossamer Bio by 119.8% during the 3rd quarter. California Public Employees Retirement System now owns 22,323 shares of the company’s stock worth $375,000 after acquiring an additional 12,165 shares during the last quarter. 61.47% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently weighed in on GOSS shares. ValuEngine cut Gossamer Bio from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price (down previously from $34.00) on shares of Gossamer Bio in a research note on Tuesday, December 17th. Berenberg Bank began coverage on Gossamer Bio in a research note on Wednesday, October 30th. They issued a “buy” rating and a $31.00 target price on the stock. Zacks Investment Research upgraded Gossamer Bio from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Bank of America began coverage on Gossamer Bio in a research note on Tuesday, December 3rd. They issued a “buy” rating and a $32.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $28.29.

GOSS stock opened at $14.67 on Wednesday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $933.12 million and a PE ratio of -0.65. Gossamer Bio has a 1-year low of $13.12 and a 1-year high of $27.15. The business’s 50 day simple moving average is $19.39 and its 200 day simple moving average is $19.70.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Tuesday, November 12th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.10). As a group, sell-side analysts predict that Gossamer Bio will post -3.05 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Read More: What is an Initial Coin Offering (ICO)?

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.